Eczema Drug Pipeline Analysis Report 2025

Eczema is a chronic skin condition that causes inflammation, redness, and itching. It affects approximately 1 in 10 people during their lifetime, making it a prevalent dermatological issue. This high prevalence drives the demand for advanced eczema therapeutic products, including innovative biologics and small-molecule drugs. The growing focus on personalized medicine and targeted therapies is accelerating the development of eczema drug candidates. With increasing investments in research and clinical trials, the pipeline is expected to grow rapidly in the coming years, offering more effective and long-lasting treatment options for patients worldwide.

Report Coverage

The Eczema Drug Pipeline Insight Report by the publisher gives comprehensive insights into eczema therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for eczema. The eczema report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The eczema pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with eczema treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to eczema.

Eczema Drug Pipeline Outlook

Eczema, also known as atopic dermatitis, is a chronic skin condition characterized by inflammation, redness, dryness, and itching. It occurs due to a combination of genetic and environmental factors that disrupt the skin barrier, making it more sensitive to irritants. Triggers include allergens, stress, weather changes, and harsh soaps, leading to flare-ups and persistent discomfort.

Eczema treatments focus on managing symptoms and preventing flare-ups. Moisturizers help to maintain skin hydration while topical corticosteroids reduce inflammation. Antihistamines relieve itching, and immunomodulators may be used for severe cases. Lifestyle adjustments, such as avoiding triggers and using gentle skincare products, are crucial. In some cases, phototherapy or advanced biologic medications may be recommended for long-term symptom control.

Eczema Epidemiology

Eczema affects approximately 1 in 10 people globally. In the United States, around 9.6 million children under 18 years have eczema, with one-third experiencing moderate to severe cases. In the United Kingdom, one in five children and one in ten adults are affected. In Japan, 10% to 20% of children have eczema, while India reports a prevalence of 2.7% to 3.6% among children.

Eczema - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of eczema drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Biologics
• Small Molecules
• Topical Corticosteroids
• Phosphodiesterase-4 (PDE4) Inhibitors
• Immunomodulators

By Route of Administration

• Oral
• Parenteral
• Others

Eczema - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total eczema clinical trials.

Eczema - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the eczema pipeline analysis include biologics, small molecules, topical corticosteroids, phosphodiesterase-4 (PDE4) inhibitors, and immunomodulators. The eczema report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for eczema.

Eczema Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the eczema drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed eczema therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in eczema clinical trials:

• Pfizer
• Eli Lilly and Company
• Evommune, Inc.
• Almirall, S.A.
• Concerto Biosciences
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Shaperon, Inc.
• Tavotek Biotherapeutics
• Celldex Therapeutics
• Incyte Corporation
• Apogee Therapeutics, Inc.
• Amgen

Eczema Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for eczema. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of eczema drug candidates.

Drug: Ruxolitinib Cream

Ruxolitinib Cream (Opzelura), sponsored by Incyte Corporation, is currently being evaluated in a Phase IV clinical trial to assess its effects on sleep disturbances in adults with atopic dermatitis. This selective JAK1/JAK2 inhibitor is already approved in the United States for treating mild to moderate atopic dermatitis in patients aged 12 and older when other therapies are ineffective or unsuitable.

Drug: Lebrikizumab

Lebrikizumab (LY3650150), sponsored by Eli Lilly and Company, is currently being evaluated in a Phase III study to assess its long-term safety and efficacy in participants aged 6 months to < 18 years with moderate-to-severe atopic dermatitis (eczema). This monoclonal antibody targets IL-13, a key driver of eczema inflammation, helping to reduce itching, dryness, and irritation.

Drug: APG777

APG777, sponsored by Apogee Therapeutics, Inc., is being evaluated in a Phase II study to assess its safety and efficacy in moderate-to-severe atopic dermatitis (AD). It is a subcutaneous, half-life extended monoclonal antibody targeting IL-13, demonstrating equal or superior potency to lebrikizumab in blocking IL-13 signaling. The study will enroll 391 participants over 106 weeks.

Reasons To Buy This Report

The Eczema Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for eczema. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into eczema collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Eczema - Pipeline Insight Report

• Which companies/institutions are leading the eczema drug development?
• What is the efficacy and safety profile of eczema pipeline drugs?
• Which company is leading the eczema pipeline development activities?
• What is the current eczema commercial assessment?
• What are the opportunities and challenges present in the eczema drug pipeline landscape?
• What is the efficacy and safety profile of eczema pipeline drugs?
• Which company is conducting major trials for eczema drugs?
• Which companies/institutions are involved in eczema collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in eczema?

This product will be delivered within 3-5 business days.